BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 25077772)

  • 1. DNA vaccine elicits an efficient antitumor response by targeting the mutant Kras in a transgenic mouse lung cancer model.
    Weng TY; Yen MC; Huang CT; Hung JJ; Chen YL; Chen WC; Wang CY; Chang JY; Lai MD
    Gene Ther; 2014 Oct; 21(10):888-96. PubMed ID: 25077772
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BET Bromodomain Inhibition Cooperates with PD-1 Blockade to Facilitate Antitumor Response in
    Adeegbe DO; Liu S; Hattersley MM; Bowden M; Zhou CW; Li S; Vlahos R; Grondine M; Dolgalev I; Ivanova EV; Quinn MM; Gao P; Hammerman PS; Bradner JE; Diehl JA; Rustgi AK; Bass AJ; Tsirigos A; Freeman GJ; Chen H; Wong KK
    Cancer Immunol Res; 2018 Oct; 6(10):1234-1245. PubMed ID: 30087114
    [No Abstract]   [Full Text] [Related]  

  • 3. Interleukin-17A Promotes Lung Tumor Progression through Neutrophil Attraction to Tumor Sites and Mediating Resistance to PD-1 Blockade.
    Akbay EA; Koyama S; Liu Y; Dries R; Bufe LE; Silkes M; Alam MM; Magee DM; Jones R; Jinushi M; Kulkarni M; Carretero J; Wang X; Warner-Hatten T; Cavanaugh JD; Osa A; Kumanogoh A; Freeman GJ; Awad MM; Christiani DC; Bueno R; Hammerman PS; Dranoff G; Wong KK
    J Thorac Oncol; 2017 Aug; 12(8):1268-1279. PubMed ID: 28483607
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantification of Kras mutant fraction in the lung DNA of mice exposed to aerosolized particulate vanadium pentoxide by inhalation.
    Banda M; McKim KL; Haber LT; MacGregor JA; Gollapudi BB; Parsons BL
    Mutat Res Genet Toxicol Environ Mutagen; 2015 Aug; 789-790():53-60. PubMed ID: 26232258
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PIK3CA(H1047R) Accelerates and Enhances KRAS(G12D)-Driven Lung Tumorigenesis.
    Green S; Trejo CL; McMahon M
    Cancer Res; 2015 Dec; 75(24):5378-91. PubMed ID: 26567140
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Loss of p53 attenuates the contribution of IL-6 deletion on suppressed tumor progression and extended survival in Kras-driven murine lung cancer.
    Tan X; Carretero J; Chen Z; Zhang J; Wang Y; Chen J; Li X; Ye H; Tang C; Cheng X; Hou N; Yang X; Wong KK
    PLoS One; 2013; 8(11):e80885. PubMed ID: 24260500
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synergistic function of Kras mutation and HBx in initiation and progression of hepatocellular carcinoma in mice.
    Ye H; Zhang C; Wang BJ; Tan XH; Zhang WP; Teng Y; Yang X
    Oncogene; 2014 Oct; 33(43):5133-8. PubMed ID: 24213574
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potentiation of Kras peptide cancer vaccine by avasimibe, a cholesterol modulator.
    Pan J; Zhang Q; Palen K; Wang L; Qiao L; Johnson B; Sei S; Shoemaker RH; Lubet RA; Wang Y; You M
    EBioMedicine; 2019 Nov; 49():72-81. PubMed ID: 31680003
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A genetically engineered mouse model developing rapid progressive pancreatic ductal adenocarcinoma.
    Yamaguchi T; Ikehara S; Nakanishi H; Ikehara Y
    J Pathol; 2014 Oct; 234(2):228-38. PubMed ID: 25042889
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vaccination with ENO1 DNA prolongs survival of genetically engineered mice with pancreatic cancer.
    Cappello P; Rolla S; Chiarle R; Principe M; Cavallo F; Perconti G; Feo S; Giovarelli M; Novelli F
    Gastroenterology; 2013 May; 144(5):1098-106. PubMed ID: 23333712
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutation-selective tumor remission with Ras-targeted, whole yeast-based immunotherapy.
    Lu Y; Bellgrau D; Dwyer-Nield LD; Malkinson AM; Duke RC; Rodell TC; Franzusoff A
    Cancer Res; 2004 Aug; 64(15):5084-8. PubMed ID: 15289309
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Kras(G12D) and Nkx2-1 haploinsufficiency induce mucinous adenocarcinoma of the lung.
    Maeda Y; Tsuchiya T; Hao H; Tompkins DH; Xu Y; Mucenski ML; Du L; Keiser AR; Fukazawa T; Naomoto Y; Nagayasu T; Whitsett JA
    J Clin Invest; 2012 Dec; 122(12):4388-400. PubMed ID: 23143308
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination wt-p53 and MicroRNA-125b Transfection in a Genetically Engineered Lung Cancer Model Using Dual CD44/EGFR-targeting Nanoparticles.
    Talekar M; Trivedi M; Shah P; Ouyang Q; Oka A; Gandham S; Amiji MM
    Mol Ther; 2016 Apr; 24(4):759-69. PubMed ID: 26686386
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A single extra copy of Dscr1 improves survival of mice developing spontaneous lung tumors through suppression of tumor angiogenesis.
    Shin J; Lee JC; Baek KH
    Cancer Lett; 2014 Jan; 342(1):70-81. PubMed ID: 24051307
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gene gun-mediated DNA vaccination induces antitumor immunity against human papillomavirus type 16 E7-expressing murine tumor metastases in the liver and lungs.
    Chen CH; Ji H; Suh KW; Choti MA; Pardoll DM; Wu TC
    Gene Ther; 1999 Dec; 6(12):1972-81. PubMed ID: 10637448
    [TBL] [Abstract][Full Text] [Related]  

  • 16. T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer.
    Tran E; Robbins PF; Lu YC; Prickett TD; Gartner JJ; Jia L; Pasetto A; Zheng Z; Ray S; Groh EM; Kriley IR; Rosenberg SA
    N Engl J Med; 2016 Dec; 375(23):2255-2262. PubMed ID: 27959684
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Higher metastatic efficiency of KRas G12V than KRas G13D in a colorectal cancer model.
    Alamo P; Gallardo A; Di Nicolantonio F; Pavón MA; Casanova I; Trias M; Mangues MA; Lopez-Pousa A; Villaverde A; Vázquez E; Bardelli A; Céspedes MV; Mangues R
    FASEB J; 2015 Feb; 29(2):464-76. PubMed ID: 25359494
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transgenic mouse model expressing P53(R172H), luciferase, EGFP, and KRAS(G12D) in a single open reading frame for live imaging of tumor.
    Ju HL; Calvisi DF; Moon H; Baek S; Ribback S; Dombrowski F; Cho KJ; Chung SI; Han KH; Ro SW
    Sci Rep; 2015 Jan; 5():8053. PubMed ID: 25623590
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NOS2 enhances KRAS-induced lung carcinogenesis, inflammation and microRNA-21 expression.
    Okayama H; Saito M; Oue N; Weiss JM; Stauffer J; Takenoshita S; Wiltrout RH; Hussain SP; Harris CC
    Int J Cancer; 2013 Jan; 132(1):9-18. PubMed ID: 22618808
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An EGFR ligand promotes EGFR-mutant but not KRAS-mutant lung cancer in vivo.
    Tomoshige K; Guo M; Tsuchiya T; Fukazawa T; Fink-Baldauf IM; Stuart WD; Naomoto Y; Nagayasu T; Maeda Y
    Oncogene; 2018 Jul; 37(28):3894-3908. PubMed ID: 29662194
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.